Celldex Therapeutics

Related records

Trials (69)

• A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
• A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
• A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
• A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
• A Phase 1 Study of CDX-0159
• A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
• A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
• A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
• A Phase I Study of CDX-622
• A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
• A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
• A Study of Barzolvolimab in Patients With Atopic Dermatitis
• A Study of Barzolvolimab in Patients With Prurigo Nodularis
• A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
• A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
• A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
• A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
• A Study of CDX-0159 in Patients With Prurigo Nodularis